※이 정보는 고수의 추천주식에서 생산한 것이 아닌 외부에서 얻은 정보를 공유하는 것입니다
※제공하는 정보는 투자판단의 참고자료이며, 투자판단의 최종책임은 본 정보를 열람하시는 이용자에게 있습니다
제넥신(095700) - 제넥신 자궁경부암 완전관해
제넥신 자궁경부암 완전관해
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30486-1/fulltext?rss=yes
제넥신
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30486-1/fulltext?rss=yes
At 24 weeks, 11 (42%; 95% CI 23-63) of 26 patients achieved an overall response; four (15%) had a complete response and seven (27%) had a partial response. 16 (44%) of 36 patients had treatment-related adverse events of any grade and four (11%) had grade 3–4 treatment-related adverse events.
4명 완전 관해, 7명 부분 관해
정보팀
0
0
0
